Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by Zacks from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday, AnalystRatingsNetwork.com reports. The brokerage currently has a $14.00 price objective on the biopharmaceutical company’s stock. Zacks‘s price objective suggests a potential upside of 20.79% from the stock’s previous close. According to Zacks, “Lexicon […]
